JP2024516730A5 - - Google Patents

Info

Publication number
JP2024516730A5
JP2024516730A5 JP2023568446A JP2023568446A JP2024516730A5 JP 2024516730 A5 JP2024516730 A5 JP 2024516730A5 JP 2023568446 A JP2023568446 A JP 2023568446A JP 2023568446 A JP2023568446 A JP 2023568446A JP 2024516730 A5 JP2024516730 A5 JP 2024516730A5
Authority
JP
Japan
Prior art keywords
substituted
pharmaceutical composition
composition according
alkyl
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516730A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027637 external-priority patent/WO2022235771A1/en
Publication of JP2024516730A publication Critical patent/JP2024516730A/ja
Publication of JP2024516730A5 publication Critical patent/JP2024516730A5/ja
Pending legal-status Critical Current

Links

JP2023568446A 2021-05-04 2022-05-04 大導電性カリウムチャネル調節剤、その組成物、その製造方法、及びその使用方法 Pending JP2024516730A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183717P 2021-05-04 2021-05-04
US63/183,717 2021-05-04
PCT/US2022/027637 WO2022235771A1 (en) 2021-05-04 2022-05-04 Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024516730A JP2024516730A (ja) 2024-04-16
JP2024516730A5 true JP2024516730A5 (https=) 2025-05-14

Family

ID=83932518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568446A Pending JP2024516730A (ja) 2021-05-04 2022-05-04 大導電性カリウムチャネル調節剤、その組成物、その製造方法、及びその使用方法

Country Status (10)

Country Link
US (1) US20240238303A1 (https=)
EP (1) EP4333852A4 (https=)
JP (1) JP2024516730A (https=)
KR (1) KR20240004887A (https=)
CN (1) CN117479945A (https=)
AU (1) AU2022270648A1 (https=)
BR (1) BR112023023075A2 (https=)
CA (1) CA3217887A1 (https=)
MX (1) MX2023013065A (https=)
WO (1) WO2022235771A1 (https=)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1330426A4 (en) * 2000-10-13 2005-09-14 Bristol Myers Squibb Co SELECTIVE MAXI-K CALIUM CHANNEL OPENING OPERATORS UNDER CONDITIONS OF HIGH INTRA-CELLULAR CALCIUM CONCENTRATIONS, METHOD AND THEIR USE
ATE488231T1 (de) * 2002-12-23 2010-12-15 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
JP2007505158A (ja) * 2003-05-21 2007-03-08 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害
US20090111868A1 (en) * 2004-12-02 2009-04-30 Marx Steven O Use Of Rottlerin And Its Derivatives As Activators Of BK Channel For Therapy Of Hypertension And Related Disorders
US8399663B2 (en) * 2009-04-03 2013-03-19 Astellas Pharma Inc. Salt of 1,3,5-triazine-2,4,6-triamine derivative
US20100256152A1 (en) * 2009-04-03 2010-10-07 Astellas Pharma Inc. Novel pharmaceutical composition for treatment of schizophrenia
GB201011905D0 (en) * 2010-07-15 2010-09-01 Unilever Plc Benefit delivery particle,process for preparing said particle,compositions comprising said particles and a method for treating substrates
AU2011336764B2 (en) * 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US20120295911A1 (en) * 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
CN102093364B (zh) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
SG11201407964YA (en) * 2012-05-29 2014-12-30 Galleon Pharmaceuticals Inc Novel compounds and compositions for treatment of breathing control disorders or diseases
SG11201503505QA (en) * 2012-11-15 2015-06-29 Galleon Pharmaceuticals Inc Novel orally bioavailable breathing control modulating compounds, and methods of using same
GB201408119D0 (en) * 2014-05-08 2014-06-25 Univ Cork Method
WO2018007331A1 (en) * 2016-07-08 2018-01-11 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives
WO2018011164A1 (en) * 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives
CN108276410B (zh) * 2017-01-06 2021-12-10 首药控股(北京)股份有限公司 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途

Similar Documents

Publication Publication Date Title
DK169333B1 (da) Fremgangsmåde til fremstilling af optisk aktive S(-)-carbazolderivater, nye S(-)-carbazolderivater, samt lægemidler, der indeholder disse forbindelser
JP2017518959A5 (https=)
US12383528B2 (en) Cromolyn esters and uses thereof
CN113365998A (zh) 用于parp抑制剂的吲哚并七元酰肟类似物
US20040138502A1 (en) Ph-dependent nmda receptor antagonists
BRPI0918134B1 (pt) Derivado de prostaglandina i2
US20240067635A1 (en) Cromolyn derivatives and uses thereof
JP2022541545A5 (https=)
JP2024540198A5 (https=)
JP2018505196A5 (https=)
JP2024546678A5 (https=)
JP2024516730A5 (https=)
JP2021527650A5 (https=)
US20230322816A1 (en) Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof
JP2002533332A (ja) 治療活性化合物としてのスルホニルオキサゾールアミン成分
JP2023510865A5 (https=)
JP2023145544A5 (https=)
JP2024504257A5 (https=)
AU2020289909B2 (en) Antihypertensive polyol compound and derivative thereof
JP2023541040A5 (https=)
JP2025501169A5 (https=)
JP2011136905A (ja) ベンゼン化合物及びその医薬用途
WO2002030872A1 (en) Novel aliphatic compounds, process for their preparation and their usage
KR930700445A (ko) 로이코트리엔-관련 질병치료용 벤조산 유도체
SU1342413A3 (ru) Способ получени производных 1,4-дигидропиридина